Common Variable Immune Deficiency/IgA Deficiency via the TNFRSF13B Gene

  • Summary and Pricing
  • Clinical Features and Genetics
  • Citations
  • Methods
  • Ordering/Specimens
Order Kits


Test Code Test Copy GenesIndividual Gene PriceCPT Code Copy CPT Codes
1692 TNFRSF13B$610.00 81479 Add to Order
Targeted Testing

For ordering targeted known variants, please proceed to our Targeted Variants landing page.

Turnaround Time

The great majority of tests are completed within 18 days.

Clinical Sensitivity

Three separate reports were able to identify causative mutations in the TNFRSF13B gene in 50 of 564 (9%) patients with hypogammaglobulinemia, 5 of 20 (25%) individuals with CVID, and 13 of 162 (8%) individuals with CVID (Salzer et al. 2009; Castigli et al. 2005; Salzer et al. 2005). In 75-80% of cases with CVID, the cause is unknown (Scharenberg et al. 2006). Analytical sensitivity should be very high as all causative variants reported to date for CVID and IgAD are detectable by this methodology.

See More

See Less

Deletion/Duplication Testing via aCGH

Test Code Test Copy GenesIndividual Gene PriceCPT Code Copy CPT Codes
600 TNFRSF13B$690.00 81479 Add to Order
Pricing Comment

# of Genes Ordered

Total Price













Over 100

Call for quote

Turnaround Time

The great majority of tests are completed within 28 days.

Clinical Features

Common Variable Immune Deficiency (CVID) is a disorder characterized by impaired humoral immunity resulting in infection susceptibility. Symptom onset is typically from age two to early adulthood with CVID affecting approximately one in 25,000 births, making it the most prevalent primary immunodeficiency. The most common genetic cause of CVID is mutation in the TNFRSF13B gene which accounts for 15-20% of cases (Salzer et al. 2005; Castigli et al. 2005). CVID may also be caused through mutations in the ICOS, BAFFR or CD19 genes and represent <1% of cases. Mutations in the TNFRSF13B gene also cause a phenotypically similar disorder, IgA Deficiency (IgAD). Genetic testing is helpful in differential diagnosis from other similar immunodeficiencies including agammaglobulinemia, ataxia-telangiectasia, severe combined immunodeficiency, WHIM syndrome, Wiskott-Aldrich syndrome, and X-linked lymphoproliferative disease (see related tests for detailed information on individual disorders). Treatment of CVID often includes immunoglobulin replacement therapy but may include splenectomy (Scharenberg et al. 2006; Wong et al. 2013). Patients with CVID through mutation in the TNFRSF13B gene are inherently susceptible to lymphoma. Therefore, genetic testing is helpful in determining if periodic CBC and WBC counts are required for surveillance of lymphoma (da Silva et al. 2011).


In 75% of CVID cases, the genetic underpinnings are unknown. The remaining cases of CVID are inherited in an autosomal dominant manner through mutations in the TNFRSF13B (15-20%) gene or an autosomal recessive mode through mutations in the ICOS, BAFFR, or CD19 genes (Scharenberg et al. 2006; Castigli and Geha 2006; Salzer et al. 2005). In rare cases, CVID has been shown to be inherited in an autosomal recessive manner through TNFRSF13B gene mutations. Mutations are found throughout the TNFRSF13B gene in CVID patients with about 90% of cases being sporadic. Two missense mutations, c.310T>C (p.Cys104Arg) and c.542C>A (p.Ala181Glu) are most commonly found and represent about 80% of all CVID cases through TNFRSF13B mutations (Salzer et al. 2009). Nonsense, splicing alterations, small insertions and small deletions have also been reported in a few cases (Salzer et al. 2009). While severity of symptoms may vary, disease penetrance is complete (Scharenberg et al. 2006).

The TNFRSF13B gene encodes the B-cell tumor necrosis factor surface receptor, transmembrane activator, and CAML interactor. Signaling by the APRIL and BAFF ligands through this receptor in conjunction with cytokine stimulation of the B-cell is required for antibody class switching which important for strengthening immunity during infection (Castigli et al. 2005).

Testing Strategy

Our DNA sequencing test involves bidirectional Sanger sequencing of the entire TNFRSF13B gene plus ~10 bp of flanking non-coding DNA on either side of each exon. We will also sequence any single exon (Test #100) in family members of patients with a known mutation or to confirm research results.

Indications for Test

Patients with CVID typically present with low serum IgG and IgA levels, recurrent Streptococcus pneumonia, Hemophilis influenza, and/or Klebsiella pneumonia infections. Other indicators of CVID include reduced CD4 T-cell counts, nodular lymphoid hyperplasia, auto-immune pneumonia, and recurrent gastrointestinal infections including Salmonella, Campylobacter, and/or Giardia (Scharenberg et al. 2006).


Official Gene Symbol OMIM ID
TNFRSF13B 604907
Inheritance Abbreviation
Autosomal Dominant AD
Autosomal Recessive AR
X-Linked XL
Mitochondrial MT


Genetic Counselors
  • Castigli E, Geha R. 2006. Molecular basis of common variable immunodeficiency. Journal of Allergy and Clinical Immunology 117: 740–746. PubMed ID: 16630927
  • Castigli E, Wilson SA, Garibyan L, Rachid R, Bonilla F, Schneider L, Geha RS. 2005. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nature Genetics 37: 829–834. PubMed ID: 16007086
  • da Silva SP, Resnick E, Lucas M, Lortan J, Patel S, Cunningham-Rundles C, Gatter K, Liu Q, Jaffe ES, Chapel H. 2011. Lymphoid Proliferations of Indeterminate Malignant Potential arising in Adults with Common Variable Immunodeficiency Disorders: Unusual Case Studies and Immunohistological Review in the Light of Possible Causative Events. Journal of Clinical Immunology 31: 784–791. PubMed ID: 21744182
  • Salzer U, Bacchelli C, Buckridge S, Pan-Hammarström Q, Jennings S, Lougaris V, Bergbreiter A, Hagena T, Birmelin J, Plebani A, others. 2009. Relevance of biallelic versus monoallelic TNFRSF13B mutations in distinguishing disease-causing from risk-increasing TNFRSF13B variants in antibody deficiency syndromes. Blood 113: 1967–1976. PubMed ID: 18981294
  • Salzer U, Chapel HM, Webster ADB, Pan-Hammarström Q, Schmitt-Graeff A, Schlesier M, Peter HH, Rockstroh JK, Schneider P, Schäffer AA, Hammarström L, Grimbacher B. 2005. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nature Genetics 37: 820–828. PubMed ID: 16007087
  • Scharenberg AM, Hannibal MC, Torgerson T, Ochs HD, Rawlings DJ. 2006. Common Variable Immune Deficiency Overview. In: Pagon RA, Adam MP, Ardinger HH, Bird TD, Dolan CR, Fong C-T, Smith RJ, and Stephens K, editors. GeneReviews(®), Seattle (WA): University of Washington, Seattle. PubMed ID: 20301476
  • Wong GK, Goldacker S, Winterhalter C, Grimbacher B, Chapel H, Lucas M, Alecsandru D, McEwen D, Quinti I, Martini H, Schmidt RE, Ernst D, et al. 2013. Outcomes of splenectomy in patients with common variable immunodeficiency (CVID): a survey of 45 patients: Splenectomy in CVID. Clinical & Experimental Immunology 172: 63–72. PubMed ID: 23480186
Order Kits

Bi-Directional Sanger Sequencing

Test Procedure

Nomenclature for sequence variants was from the Human Genome Variation Society (  As required, DNA is extracted from the patient specimen.  PCR is used to amplify the indicated exons plus additional flanking non-coding sequence.  After cleaning of the PCR products, cycle sequencing is carried out using the ABI Big Dye Terminator v.3.0 kit.  Products are resolved by electrophoresis on an ABI 3730xl capillary sequencer.  In most cases, sequencing is performed in both forward and reverse directions; in some cases, sequencing is performed twice in either the forward or reverse directions.  In nearly all cases, the full coding region of each exon as well as 10 bases of non-coding DNA flanking the exon are sequenced.

Analytical Validity

As of February 2018, we compared 26.8 Mb of Sanger DNA sequence generated at PreventionGenetics to NextGen sequence generated in other labs. We detected only 4 errors in our Sanger sequences, and these were all due to allele dropout during PCR. For Proficiency Testing, both external and internal, in the 14 years of our lab operation we have Sanger sequenced roughly 14,300 PCR amplicons. Only one error has been identified, and this was an error in analysis of sequence data.

Our Sanger sequencing is capable of detecting virtually all nucleotide substitutions within the PCR amplicons. Similarly, we detect essentially all heterozygous or homozygous deletions within the amplicons. Homozygous deletions which overlap one or more PCR primer annealing sites are detectable as PCR failure. Heterozygous deletions which overlap one or more PCR primer annealing sites are usually not detected (see Analytical Limitations). All heterozygous insertions within the amplicons up to about 100 nucleotides in length appear to be detectable. Larger heterozygous insertions may not be detected. All homozygous insertions within the amplicons up to about 300 nucleotides in length appear to be detectable. Larger homozygous insertions may masquerade as homozygous deletions (PCR failure).

Analytical Limitations

In exons where our sequencing did not reveal any variation between the two alleles, we cannot be certain that we were able to PCR amplify both of the patient’s alleles. Occasionally, a patient may carry an allele which does not amplify, due for example to a deletion or a large insertion. In these cases, the report contains no information about the second allele.

Similarly, our sequencing tests have almost no power to detect duplications, triplications, etc. of the gene sequences.

In most cases, only the indicated exons and roughly 10 bp of flanking non-coding sequence on each side are analyzed. Test reports contain little or no information about other portions of the gene, including many regulatory regions.

In nearly all cases, we are unable to determine the phase of sequence variants. In particular, when we find two likely causative mutations for recessive disorders, we cannot be certain that the mutations are on different alleles.

Our ability to detect minor sequence variants, due for example to somatic mosaicism is limited. Sequence variants that are present in less than 50% of the patient’s nucleated cells may not be detected.

Runs of mononucleotide repeats (eg (A)n or (T)n) with n >8 in the reference sequence are generally not analyzed because of strand slippage during PCR and cycle sequencing.

Unless otherwise indicated, the sequence data that we report are based on DNA isolated from a specific tissue (usually leukocytes). Test reports contain no information about gene sequences in other tissues.

Deletion/Duplication Testing via Array Comparative Genomic Hybridization

Test Procedure

Equal amounts of genomic DNA from the patient and a gender matched reference sample are amplified and labeled with Cy3 and Cy5 dyes, respectively. To prevent any sample cross contamination, a unique sample tracking control is added into each patient sample. Each labeled patient product is then purified, quantified, and combined with the same amount of reference product. The combined sample is loaded onto the designed array and hybridized for at least 22-42 hours at 65°C. Arrays are then washed and scanned immediately with 2.5 µM resolution. Only data for the gene(s) of interest for each patient are extracted and analyzed.

Analytical Validity

PreventionGenetics' high density gene-centric custom designed aCGH enables the detection of relatively small deletions and duplications within a single exon of a given gene or deletions and duplications encompassing the entire gene. PreventionGenetics has established and verified this test's accuracy and precision.

Analytical Limitations

Our dense probe coverage may allow detection of deletions/duplications down to 100 bp; however due to limitations and probe spacing this cannot be guaranteed across all exons of all genes. Therefore, some copy number changes smaller than 100-300 bp within a targeted large exon may not be detected by our array.

This array may not detect deletions and duplications present at low levels of mosaicism or those present in genes that have pseudogene copies or repeats elsewhere in the genome.

aCGH will not detect balanced translocations, inversions, or point mutations that may be responsible for the clinical phenotype.

Breakpoints, if occurring outside the targeted gene, may be hard to define.

The sensitivity of this assay may be reduced when DNA is extracted by an outside laboratory.

Order Kits

Ordering Options

myPrevent - Online Ordering
  • The test can be added to your online orders in the Summary and Pricing section.
  • Once the test has been added log in to myPrevent to fill out an online requisition form.
  • A completed requisition form must accompany all specimens.
  • Billing information along with specimen and shipping instructions are within the requisition form.
  • All testing must be ordered by a qualified healthcare provider.


(Delivery accepted Monday - Saturday)

  • Collect 3 ml -5 ml (5 ml preferred) of whole blood in EDTA (purple top tube) or ACD (yellow top tube). For Test #500-DNA Banking only, collect 10 ml -20 ml of whole blood.
  • For small babies, we require a minimum of 1 ml of blood.
  • Only one blood tube is required for multiple tests.
  • Ship blood tubes at room temperature in an insulated container. Do not freeze blood.
  • During hot weather, include a frozen ice pack in the shipping container. Place a paper towel or other thin material between the ice pack and the blood tube.
  • In cold weather, include an unfrozen ice pack in the shipping container as insulation.
  • At room temperature, blood specimen is stable for up to 48 hours.
  • If refrigerated, blood specimen is stable for up to one week.
  • Label the tube with the patient name, date of birth and/or ID number.


(Delivery accepted Monday - Saturday)

  • Send in screw cap tube at least 5 µg -10 µg of purified DNA at a concentration of at least 20 µg/ml for NGS and Sanger tests and at least 5 µg of purified DNA at a concentration of at least 100 µg/ml for gene-centric aCGH, MLPA, and CMA tests, minimum 2 µg for limited specimens.
  • For requests requiring more than one test, send an additional 5 µg DNA per test ordered when possible.
  • DNA may be shipped at room temperature.
  • Label the tube with the composition of the solute, DNA concentration as well as the patient’s name, date of birth, and/or ID number.
  • We only accept genomic DNA for testing. We do NOT accept products of whole genome amplification reactions or other amplification reactions.


(Delivery preferred Monday - Thursday)

  • PreventionGenetics should be notified in advance of arrival of a cell culture.
  • Culture and send at least two T25 flasks of confluent cells.
  • Some panels may require additional flasks (dependent on size of genes, amount of Sanger sequencing required, etc.). Multiple test requests may also require additional flasks. Please contact us for details.
  • Send specimens in insulated, shatterproof container overnight.
  • Cell cultures may be shipped at room temperature or refrigerated.
  • Label the flasks with the patient name, date of birth, and/or ID number.
  • We strongly recommend maintaining a local back-up culture. We do not culture cells.
loading Loading... ×